Overview

Join our distinguished faculty as they discuss their experiences recognizing, diagnosing, and managing adult patients with polyneuropathy caused by hereditary transthyretin-mediated (hATTR) amyloidosis. They will provide an overview of hATTR amyloidosis and discuss their collaborative approach to diagnosis, share two case studies, and review the clinical profile of ONPATTRO^® (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. ONPATTRO has warnings and precautions for infusion-related reactions (IRRs) and reduced serum vitamin A levels with recommended supplementation. The most common adverse reactions are upper respiratory tract infections and IRRs. For additional information about ONPATTRO, please see the Important Safety Information and full Prescribing Information.

This program is intended for U.S. Healthcare Professionals only.

Disclaimers

The content in this Contemporary Forum is created independently by the sponsor. The views and/or opinions expressed in this forum do not purport to reflect the opinions or views of the HFSA or its members.

The activity Multispecialty Perspectives on Recognizing, Diagnosing and Managing Polyneuropathy Caused by hATTR Amyloidosis is not sponsored or endorsed by the HFSA.

The Contemporary Forum is not offered in the HFSA-accredited continuing education catalog; therefore, it is ineligible for continuing education units.